Trends in Use of Melatonin Supplements Among US Adults, 1999-2018

Jingen Li,Virend K. Somers,Hao Xu,Francisco Lopez-Jimenez,Naima Covassin

DOI: https://doi.org/10.1001/jama.2021.23652

IF: 11.816

2022-02-01

JAMA

Abstract:This study examines reported prevalence and trends in use of melatonin supplements among US adults from 1999 through 2018.

medicine, general & internal

What problem does this paper attempt to address?

Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies

Yanping Li,Tianyi Huang,Susan Redline,Walter C Willett,JoAnn E Manson,Eva S Schernhammer,Frank B Hu

DOI: https://doi.org/10.1016/S2213-8587(24)00096-2

Abstract:Background: Use of melatonin supplements has been increasing substantially in both children and adults in the USA; however, their long-term cardiometabolic effects remain unclear. We aimed to assess the associations between regular use of melatonin supplements and the risk of developing type 2 diabetes or cardiovascular disease in adults. Methods: In this study, we included individuals from three US cohorts: the Nurses' Health Study (women only), the Health Professionals Follow-up Study (men only), and the Nurses' Health Study II (women only). Women aged 25-55 years and men aged 45-75 years at baseline, who had no diagnosis of cancer at baseline, and who responded to the question about melatonin supplement use (yes or no) were included. We excluded baseline prevalent cardiovascular disease and baseline prevalent type 2 diabetes for the main analyses. The main outcomes were cardiovascular disease and type 2 diabetes incidence. In secondary analyses, we stratified by duration of rotating night shift work in the Nurses' Health Study and Nurses' Health Study II to examine whether the associations with melatonin supplement use differed by rotating night shift work. Findings: For the cardiovascular disease analysis, we included 67 202 women from the Nurses' Health Study (follow-up 1998-2019, mean age at baseline: 63·6 years [SD 7·1]), 26 629 men from the Health Professionals Follow-up Study (1998-2020, 62·9 years [8·8], and 65 241 women from the Nurses' Health Study II (2003-19, 48·2 years [4·7]). Follow-up for incident type 2 diabetes was from 1998 to June 30, 2021, for the Nurses' Health Study; 2003 to Jan 31, 2023, for the Nurses' Health Study II; and from 1998 to Jan 31, 2020, for the Health Professionals' Follow-up Study. Melatonin supplement use in the study cohorts doubled over recent decades from less than 2% in 1998-2007 to 4% or higher in 2014-15 (4·0% in men and 5·3% in women). We documented 16 917 incident cardiovascular disease events during 2 609 068 person-years of follow-up and 12 730 incident cases of type 2 diabetes during 2 701 830 person-years of follow-up. In a pooled analysis of the three cohorts, comparing users with non-users of melatonin supplements, the pooled multivariable-adjusted hazard ratios were 0·94 (95% CI 0·83-1·06, p=0·32) for cardiovascular disease and 0·98 (0·86-1·12, p=0·80) for type 2 diabetes. In secondary analyses, melatonin supplement use appeared to attenuate the positive association between long-term shift work (>5 years) and risk of cardiovascular disease (pinteraction=0·013) among the female nurses. Interpretation: With up to 23 years of follow-up of three large prospective cohorts of middle-aged and older men and women, self-reported melatonin supplement use was not associated with risk of type 2 diabetes or cardiovascular disease. Further research is warranted to assess if melatonin supplement use could mitigate the potential risks of type 2 diabetes and cardiovascular disease associated with rotating night shift work. Funding: US National Institutes of Health.
0817 Influencing Factors in the Decision-Making Process of U.S. Parents Regarding the Use of Melatonin for Children

Lauren Hartstein,Michelle Garrison,Daniel Lewin,Julie Boergers,Brandon Hiraki,John Harsh,Monique LeBourgeois

DOI: https://doi.org/10.1093/sleep/zsae067.0817

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction Parents are increasingly turning to exogenous melatonin to help children sleep, despite a lack of experimental research examining its efficacy and the safety of long-term use. In the U.S., melatonin is classified as a dietary supplement and no prescription is needed to obtain it. Given recent surges in pediatric consumption, current data on the factors contributing to parents’ decisions to administer melatonin to their children are vital in order to understand perceptions and concerns surrounding its use. Methods Parents of 1039 U.S. children ages 1.0-13.9 years completed an online questionnaire on children’s development, sleep health, and melatonin use. Data on 212 children who either took melatonin in the past 30 days (N = 131) or at some point previously (N = 81) were included in the present analysis. Open-ended questions on why parents administered melatonin and why they stopped (if applicable) were categorized through thematic coding. Results Although nearly half of children who recently took melatonin had bedtime resistance (51.1%) or difficulty falling asleep (46.2%), 24.4% had no reported behavioral sleep problems. Parents’ most common reasons for giving melatonin were to help children fall asleep (49.3%) or wind down before bedtime (22.7%). Parents also reported administering it to adjust for changes to regular sleep routines (17.5%) or to shift circadian rhythms (11.4%). Parents frequently reported initiating melatonin on their own (50.0%), with less than half following the recommendation of a healthcare provider (48.1%). Parents often stopped giving melatonin when they felt their child didn’t need it anymore (32.0%). Fewer parents discontinued use due to negative side effects (9.3%) or concerns about health and safety (13.3%). Conclusion Parents reported giving their child melatonin for a variety of reasons related to sleep and circadian timing. Melatonin use was frequently initiated without the recommendation of a medical professional, which raises concerns about misinformation given the gaps in scientific research and variable quality of over-the-counter supplements. Greater research and wider dissemination of guidelines are needed to support parents in making informed decisions regarding their child’s melatonin use. Support (if any) Eunice Kennedy Shriver National Institute of Child Health & Human Development (F32-HD103390; R01-HD087707)

neurosciences,clinical neurology
Prevalence and trends in dietary supplement use among US adults with diabetes: the National Health and Nutrition Examination Surveys, 1999-2014

Jing Li,Xinli Li,Wambui Gathirua-Mwangi,Yiqing Song

DOI: https://doi.org/10.1136/bmjdrc-2019-000925

2020-01-01

BMJ Open Diabetes Research & Care

Abstract:Objective To evaluate overall prevalence and trends of use of any supplements, multivitamins/multiminerals (MVMM), individual vitamins, minerals, and non-vitamin, non-mineral (NVNM) supplements among adults with diabetes in the USA. Research design and methods We used a nationally representative sample from the National Health and Nutrition Examination Survey collected between 1999 and 2014. Information on supplement use in the preceding 30 days was collected during interview over 8 continuous 2-year waves. To account for the complex sampling design, weighted analyses were conducted among 6688 US adults with diabetes aged 20-85 years and also stratified by age, sex, race/ethnicity, education, comorbidity status, and diabetes duration. Results Overall, the prevalence of any supplement use (52%-58%;Pfor trend=0.08) and that of any mineral use (47%-51%;Pfor trend=0.23) seemed stable over the years studied. Reported use of MVMM slightly decreased from 36% to 32% (Pfor trend=0.006). Use of any vitamin products significantly increased from 47% to 52% (Pfor trend=0.03). Use of some individual supplements, especially vitamin D, choline, lycopene, and fish oil supplements, significantly increased, while some vitamins, minerals and NVNM supplements decreased over the years. In addition, the trend of any supplement use varied by age, sex, race/ethnicity, or education, but not by diabetes duration or diabetic comorbidities. Conclusions Among US patients with diabetes, use of any dietary supplements or any minerals remained stable, while MVMM use slightly decreased and use of any vitamins increased. Additionally, use of several individual supplements varied significantly over the 16-year period studied.
A Survey of Melatonin in Dietary Supplement Products Sold in the United States

Rahul S. Pawar,Julia P. Coppin,Saara Khanna,Christine H. Parker

DOI: https://doi.org/10.1002/dta.3823

2024-11-02

Drug Testing and Analysis

Abstract:An LC‐MS/MS method was validated to measure melatonin and two degradation products in dietary supplements in a broad range of product forms, including gummy, liquid, tablet, capsule, and other edibles. The method was used to analyze 110 dietary supplement products intended for children and labeled to contain melatonin. In the United States, melatonin products are widely available as dietary supplements. During the past few decades, melatonin products have gained popularity primarily as a sleep aid, with a variety of product forms available for different age groups of consumers. Recent reports have highlighted a rise in melatonin ingestion among children reported to poison control centers. The increased use of melatonin‐containing products, the diversity in product forms, and reported label discrepancies has emphasized the need for additional research to better understand the marketplace. This work aims to measure melatonin content in products sold as dietary supplements and marketed for children, evaluate method performance across different product categories, and determine if product form has an impact on melatonin stability. One hundred ten (110) dietary supplement products labeled to contain melatonin and marketed towards children were purchased and analyzed using a targeted LC‐MS/MS method validated for the qualitative determination of serotonin and quantification of melatonin, N1‐acetyl‐N2‐formyl‐5‐methoxykynuramine (AFMK), and N1‐acetyl‐5‐methoxykynuramine (AMK). Melatonin was identified in 108 of 110 products (98%) with a median concentration of 1.2 mg/g (range: 0.017–130 mg/g) or 1.7 mg/serving (range: 0.042–50 mg/serving). Further, in the tested products, melatonin content ranged from 0% to 667% of the label declaration. This study provides evidence to inform safety assessments and investigate potential factors that may influence reported concentrations, such as product stability and matrix influences.

pharmacology & pharmacy,biochemical research methods,chemistry, analytical
Melatonin Use in Pediatrics: A Clinical Review on Indications, Multisystem Effects, and Toxicity

Pranita Shenoy,Adriana Etcheverry,Jalyn Ia,Manisha Witmans,Mary Anne Tablizo

DOI: https://doi.org/10.3390/children11030323

2024-03-09

Children

Abstract:Exogenous melatonin is typically used for sleep regulation in the context of insomnia either in healthy children or those with neurodevelopmental disabilities. It is also used for the management of circadian rhythm sleep disorders in pediatric and adolescent patients. There are also many other possible indications that we will discuss in this paper beyond the role of melatonin for sleep regulation, including its potential use for various areas of medicine such as inflammatory conditions. Since melatonin is unregulated in the United States, distributed over the counter and perceived to be natural and safe, it has become available in many forms in the last two decades. With increasing sleep disturbances and mental health problems after the COVID-19 pandemic, melatonin has become even more popular and studies have shown a dramatic increase in use as well as resulting side effects, including melatonin overdose. As melatonin is generally viewed by physicians as a benign medication, we hope to increase awareness of melatonin’s properties as well as negative side effects to optimize its use in the pediatric population.

pediatrics
Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content.

Lauren A. E. Erland,P. Saxena

DOI: https://doi.org/10.5664/jcsm.6462

2017-02-15

Abstract:STUDY OBJECTIVES Melatonin is an important neurohormone, which mediates circadian rhythms and the sleep cycle. As such, it is a popular and readily available supplement for the treatment and prevention of sleep-related disorders including insomnia and jet lag. This study quantified melatonin in 30 commercial supplements, comprising different brands and forms and screened supplements for the presence of serotonin. METHODS A total of 31 supplements were analyzed by ultraperformance liquid chromatography with electrochemical detection for quantification of melatonin and serotonin. Presence of serotonin was confirmed through analysis by ultraperformance liquid chromatography with mass spectrometry detection. RESULTS Melatonin content was found to range from -83% to +478% of the labelled content. Additionally, lot-to-lot variable within a particular product varied by as much as 465%. This variability did not appear to be correlated with manufacturer or product type. Furthermore, serotonin (5-hydroxytryptamine), a related indoleamine and controlled substance used in the treatment of several neurological disorders, was identified in eight of the supplements at levels of 1 to 75 μg. CONCLUSIONS Melatonin content did not meet label within a 10% margin of the label claim in more than 71% of supplements and an additional 26% were found to contain serotonin. It is important that clinicians and patients have confidence in the quality of supplements used in the treatment of sleep disorders. To address this, manufacturers require increased controls to ensure melatonin supplements meet both their label claim, and also are free from contaminants, such as serotonin. COMMENTARY A commentary on this article appears in this issue on page 163.

Chemistry,Medicine
Melatonin and Age-Related Macular Degeneration Risk

Hejin Jeong,Jacqueline K. Shaia,Jonathan C. Markle,Katherine E. Talcott,Rishi P. Singh

DOI: https://doi.org/10.1001/jamaophthalmol.2024.1822

IF: 8.253

2024-07-19

JAMA Ophthalmology

Abstract:This cohort study examines the association between melatonin supplementation and the risk of development or progression of age-related macular degeneration in older US adults.

ophthalmology
Gender differences in the prevalence of and trends in sleep patterns and prescription medications for insomnia among US adults, 2005 to 2018

Lei Zuo,Xia Chen,Mingliang Liu,Shan Dong,Li Chen,Guangzhen Li,Zhiyu Zhai,Long Zhou,Haiyan Chen,Yuan Wei,Liping Shi,Guang Hao

DOI: https://doi.org/10.1016/j.sleh.2022.07.004

IF: 4.207

Sleep Health

Abstract:Background: Evidence indicates that the burden of sleep disorders is increasing, yet recent trends have not been examined. Objective: To examine the prevalence of and trends in sleep patterns and medications commonly used for insomnia (MCUFI) in US adults from 2005 through 2018. Methods: A total of 39,749 participants aged 20 years or older from 7 consecutive National Health and Nutrition Examination Survey cycles during 2005-2018 were included. Results: The age-standardized prevalence of trouble sleeping and using MCUFI was higher in women than men, but men tended to sleep less (sleep duration <7 hours) and were more likely to have sleep disorders. The temporal trends in sleep disorders and MCUFI were similar in men and women, except that trouble sleeping increased more in men (P = 0.024). The prevalence of insufficient sleep decreased from 33.6% in women and 38.1% in men in 2005-2006 to 20.5% in women and 28.6% in men in 2017-2018. The prevalence of MCUFI use was 13.3% in women and 8.9% in men in 2005-2006, peaked at 15.2% for men and 17.0% for women in 2013-2014, and decreased slightly in 2015-2018. Conclusion: The prevalence of trouble sleeping and MCUFI use was higher in women, while the prevalence of short sleep duration and sleep disorders was higher in men. Sleep disorders, abnormal sleep duration, and MCUFI use increased at a broadly similar pace in men and women, except that trouble sleeping increased more in men.
Unintended consequences: college students' melatonin usage, sleep disturbance, and depressive symptoms

Jack S Peltz,Ronald Rogge

DOI: https://doi.org/10.1007/s41105-023-00506-9

2023-12-22

Abstract:With such high rates of undergraduate sleep problems, students have chosen to take melatonin, an over-the-counter supplement that can facilitate sleep. Questions remain as to the effectiveness of melatonin for sleep problems, and questions have emerged about its impact on mental health. Accordingly, the current study examined how ongoing melatonin usage might impact relative changes in college students' sleep disturbance and ultimately their depressive symptoms. The two-wave (baseline and 2-month follow-up), online sample consisted of 331 undergraduates (86% female; Mage = 21.3, SD = 2.4), who reported on melatonin usage, sleep disturbance, and depressive symptoms. Controlling for sleep hygiene, socio-economic status, and gender, our model demonstrated a significant indirect effect from ongoing melatonin usage to depressive symptoms. Specifically, melatonin consumption predicted relative increases in sleep disturbance, which, in turn, predicted corresponding increases in students' depressive symptoms. Given the increasing prevalence of melatonin usage, the potential for unforeseen consequences remains high. Results suggest that the negative consequences of melatonin use can include both college students' mental health and their sleep. Given the efficacy of addressing sleep problems with cognitive or behavioral strategies, it is essential that student support services highlight alternatives to melatonin and the potential problems associated with its use.
Patterns of Melatonin Use in a Diverse National Pediatric Sample

Ekaterina Sadikova,Divyangana Rakesh,Henning Tiemeier

DOI: https://doi.org/10.1001/jamanetworkopen.2024.12502

2024-05-23

JAMA Network Open

Abstract:This cohort study examines patterns of melatonin use among participants in the Adolescent Brain Cognitive Development (ABCD) Study and characterizes factors associated with use.

medicine, general & internal
Is Melatonin the "Next Vitamin D"?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements

Deanna M Minich,Melanie Henning,Catherine Darley,Mona Fahoum,Corey B Schuler,James Frame

DOI: https://doi.org/10.3390/nu14193934

IF: 5.9

2022-09-22

Nutrients

Abstract:Melatonin has become a popular dietary supplement, most known as a chronobiotic, and for establishing healthy sleep. Research over the last decade into cancer, Alzheimer's disease, multiple sclerosis, fertility, PCOS, and many other conditions, combined with the COVID-19 pandemic, has led to greater awareness of melatonin because of its ability to act as a potent antioxidant, immune-active agent, and mitochondrial regulator. There are distinct similarities between melatonin and vitamin D in the depth and breadth of their impact on health. Both act as hormones, affect multiple systems through their immune-modulating, anti-inflammatory functions, are found in the skin, and are responsive to sunlight and darkness. In fact, there may be similarities between the widespread concern about vitamin D deficiency as a "sunlight deficiency" and reduced melatonin secretion as a result of "darkness deficiency" from overexposure to artificial blue light. The trend toward greater use of melatonin supplements has resulted in concern about its safety, especially higher doses, long-term use, and application in certain populations (e.g., children). This review aims to evaluate the recent data on melatonin's mechanisms, its clinical uses beyond sleep, safety concerns, and a thorough summary of therapeutic considerations concerning dietary supplementation, including the different formats available (animal, synthetic, and phytomelatonin), dosing, timing, contraindications, and nutrient combinations.
Melatonin Use in School-Aged Children and Adolescents: An Exploration of Caregiver and Pharmacist Perspectives

Samantha K M Lee,Kingston W C M Yeung,Yu Sun Bin,Lorraine Smith,Edwin C K Tan,Rose Cairns,Janet M Y Cheung

DOI: https://doi.org/10.1080/15402002.2024.2396838

Abstract:Objective: This study aims to explore the perspectives and experiences of Australian caregivers and community pharmacists about pediatric melatonin use. Methods: A convenience sample of caregivers with children (aged 11-16 years) using melatonin as a sleep aid and community pharmacists (including pharmacist interns) were recruited. Participants first completed an online survey followed by an online semi-structured interview. Interviews were guided by a schedule of questions for the respective participant groups, broadly exploring their beliefs about melatonin, experiences in using/supplying melatonin, and perceived facilitators/barriers for melatonin use. Interviews were digitally recorded, transcribed verbatim, and analyzed using the Framework Approach. Results: Fourteen caregivers of predominantly neurodiverse adolescents and 24 community pharmacists were interviewed. While melatonin was perceived by caregivers of both typically developing and neurodiverse dependants as safer than pharmacological sleep aids, treatment was only initiated after trialling non-pharmacological strategies first. Pharmacists expressed concerns around the ambiguities in practice and the limited scope of existing resources for guiding pediatric melatonin use. Caregivers frequently deferred to the information available online to procure products or self-adjust doses and dosing schedules. Both pharmacists and caregivers emphasized the need for more affordable and age-appropriate proprietary formulations that are readily accessible. Conclusion: Melatonin is administered predominantly by caregivers of neurodiverse adolescents to address their sleep disturbances. The findings underscore the need for reliable, evidence-based information to guide safe and appropriate use of melatonin in pediatric populations. Patient education is also warranted to address maladaptive medication-administration practices. Lastly, there is a need for stronger regulatory oversight of melatonin products to ensure their quality and safety of use.
Quality of melatonin use in children and adolescents: findings from a UK clinical audit

Carol Paton,Paul Gringras,Alice Ruan,Ashley Liew,Olivia Rendora,Gaia Bove,Thomas R E Barnes

DOI: https://doi.org/10.1136/bmjment-2023-300894

2024-01-23

Evidence-Based Mental Health

Abstract:Background Melatonin is commonly used to treat sleep disturbance in children and adolescents, although uncertainties about its optimal use remain. Objective To determine to what extent prescribing of melatonin complies with evidence-based clinical practice standards. Methods As part of a quality improvement programme, the Prescribing Observatory for Mental Health conducted a retrospective clinical audit in UK services for children and adolescents. Findings Data were submitted for 4151 children and adolescents up to 18 years of age, treated with melatonin: 3053 (74%) had a diagnosis of neurodevelopmental disorder. In 2655 (73%) of the 3651 patients prescribed melatonin to be taken regularly, the main reason was to reduce sleep latency (time taken to fall asleep). In 409 patients recently starting melatonin, a non-pharmacological intervention had already been tried in 279 (68%). The therapeutic response of patients early in treatment (n=899) and on long-term treatment (n=2353) had been assessed and quantified in 36% and 31%, respectively, while for review of side effects, the respective proportions were 46% and 43%. Planned treatment breaks were documented in 317 (13%) of those on long-term treatment. Conclusions Melatonin was predominantly prescribed for evidence-based clinical indications, but the clinical review and monitoring of this treatment fell short of best practice. Clinical implications With limited methodical review of melatonin use in their patients, clinicians will fail to garner reliable information on its risks and benefits for individual patients. The lack of such practice-based evidence may increase the risk of melatonin being inappropriately targeted or continued despite being ineffective or no longer indicated.

psychiatry
Analysis of sleep for the American population: Result from NHANES database

Qiurui Nie,Yu Shen,Mengqin Luo,Zhiyong Sheng,Rui Zhou,Guangmin Li,Wei Huang,Shenjian Chen

DOI: https://doi.org/10.1016/j.jad.2023.11.082

IF: 6.533

2023-11-23

Journal of Affective Disorders

Abstract:Objectives To assess the contemporary prevalence and decade-long trends of sleep duration, sleep disorders and trouble sleeping among adults in the United States, as well as their risk factors, from 2005 to 2018. Materials and methods We used National Health and Nutrition Examination Survey data to calculate the sleep duration and weighted prevalence of sleep disorders and trouble sleeping in adults aged 20 years or older. Sleep duration, sleep disorders and trouble sleeping were assessed by questionnaire. Results A total of 27,399 people were included in the survey on sleep duration, with a weighted percentage of normal sleep (7–8 h/night) of 56.33 % (95 % CI, 53.06–59.60 %) and a weighted percentage of short sleep (5–6 h/night) of 31.73 %. In stratified descriptions, participants aged 40–49 years were more likely to sleep less than five hours, while women aged 80 years and older were more likely to sleep longer and blacks were more likely to sleep shorter. A total of 27,406 participants were included in the survey for sleep disorders. The weighted proportion of the population with sleep disorders was 8.44 % (95 % CI, 7.79–9.8 %). Independent risk factors for sleep disorders were being 40–69 years old, being white, having a high education level, smoking, having hypertension, diabetes, heart disease, and BMI ≥ 25. From 2005 to 2014, the prevalence of sleep disorders increased year by year, from 7.44 % in 2005–2006 to 10.40 % in 2013–2014 ( P for Trend<0.001). A total of 38,165 participants were included in the survey on trouble sleeping. The weighted proportion of the population with troubled sleeping was 27.30 % (25.70–28.90 %). Independent risk factors for troubled sleeping were being 30–79 years old, being white, having a high education level, smoking, drinking, having hypertension, diabetes, heart disease and BMI ≥ 25. From 2005 to 2018, the prevalence of trouble sleeping increased annually, from 24.44 % in 2005–2006 to 30.58 % in 2017–2018 ( P for trend<0.001). Conclusion Adults in the United States are likely to have abnormal sleep durations, and the prevalence of sleep disorders and troubled sleeping is on the rise.

psychiatry,clinical neurology
Notes from the Field: Emergency Department Visits for Unsupervised Pediatric Melatonin Ingestion — United States, 2019–2022

Devin I Freeman,Jennifer N Lind,Nina J Weidle,Andrew I Geller,Nimalie D Stone,Maribeth C Lovegrove,Devin I. Freeman,Jennifer N. Lind,Nina J. Weidle,Andrew I. Geller,Nimalie D. Stone,Maribeth C. Lovegrove

DOI: https://doi.org/10.15585/mmwr.mm7309a5

2024-03-09

MMWR Morbidity and Mortality Weekly Report

Abstract:This report describes emergency department visits for unsupervised melatonin ingestion by infants and young children.

public, environmental & occupational health
Effect of melatonin supplementation on body composition and blood pressure in adults: A systematic review and Dose-Response meta-analysis of randomized controlled trial

Mahdi Vajdi,Seyedehelham Moeinolsadat,Nooshin Noshadi,Fatemeh Pourteymour Fard Tabrizi,Mahsa Khajeh,Mahdieh Abbasalizad-Farhangi,Beitullah Alipour

DOI: https://doi.org/10.1016/j.heliyon.2024.e34604

IF: 3.776

2024-07-14

Heliyon

Abstract:Background: Several randomized controlled trials (RCTs) have explored the impact of melatonin on body composition and blood pressure (BP). However, the findings from these studies remain a topic of debate. This systematic review and meta-analysis of RCTs sought to evaluate the effects of melatonin consumption on body composition (body weight (BW), body mass index (BMI), waist circumference (WC), hip circumference (HC)) and asleep/daytime BP (systolic blood pressure (SBP) and diastolic blood pressure (DBP)) in adults. Methods: In order to identify eligible RCTs, a systematic literature search was carried out up to June 2024 in PubMed, Embase, Scopus, and Web of Science without any language restrictions. The I2 statistic was used to perform heterogeneity tests on the selected studies. After evaluating random effects models based on heterogeneity tests, the weighted mean differences (WMD) with a 95 % confidence interval (CI) were calculated using pooled data. Results: Overall, 28 studies (n = 1,543 participants) met our inclusion criteria. A pooled analysis of studies demonstrated that melatonin consumption led to a significant reduction in HC (WMD: 1.21 cm; 95 % CI: 1.94 to -0.49; P = 0.001), and daytime DBP (WMD: 1.40 mmHg; 95 % CI: 2.46 to -0.34; P = 0.009) in comparison with the control group. However, no substantial effects were observed on BW, BMI, WC, and SBP compared to the control group. Conclusion: The current meta-analysis of RCTs shows that treatment with melatonin reduces HC and daytime DBP levels in adults. However, further well-designed RCTs with large sample sizes and long durations are necessary to determine the effect of this supplement on body composition and BP.
Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis

Kyle Smoot,Tiffany Gervasi-Follmar,Horia Marginean,Chiayi Chen,Stanley Cohan

DOI: https://doi.org/10.1016/j.msard.2024.105799

2024-08-03

Abstract:Introduction: Melatonin is an antioxidant and anti-inflammatory agent that modulates the immune system by scavenging free radicals, reducing the upregulation of pro-inflammatory cytokines, and reducing transendothelial cell migration. Therefore, melatonin may play a role in regulating multiple sclerosis (MS) disease activity. However, little is known about how melatonin supplementation effects individuals with MS. Objective: Determine if there was a dose-dependent elevation in urine and serum melatonin concentrations. Determine if melatonin supplementation had an impact on patient reported outcomes. Methods: This was a randomized, dose-blinded exploratory study. Adults (age 18-65) with relapsing forms of multiple sclerosis (RMS) treated with a stable dose of oral disease modifying therapy for at least 6 months were randomized into melatonin 3 mg or 5 mg daily. Urinary and serum melatonin levels and modified fatigue impact scale (MFIS), multiple sclerosis impact scale (MSIS-29), and Pittsburgh sleep quality index (PSQI), patient determined disease steps (PDDS) and performance scales (PS) were measured at baseline, 3, 6, and 12 months. Urinary and serum melatonin analyses was performed to estimate mean concentrations and their differences between treatment arms over time by a repeated measures linear mixed model. The model included treatment, assessment time, and treatment × time interaction. Results: Thirty patients, randomized 1:1, were analyzed in an intent to treat population. Twenty-three completed the study. The repeated measures linear mixed model analysis of all timepoints revealed higher melatonin concentrations in patients on 5 mg compared to 3 mg melatonin for both urinary 6-SMT (p = 0.03) and serum melatonin (p = 0.04). MFIS, MSIS-29, PSQI, and PDSS-PS scores did not significantly change from baseline to month 12. No significant differences in these measures were seen between the two doses. Five patients stopped melatonin (three on 5 mg and two on 3 mg) due to adverse events, including one patient who developed focal spongiotic dermatitis. One patient experienced three consecutive serious adverse events that were unrelated to melatonin supplementation. Conclusions: The 5 mg melatonin supplementation group had higher concentrations of urinary 6-SMT and serum melatonin compared to the 3 mg group over 12 months of treatment. There was a correlation between 6-SMT and serum melatonin concentrations. This suggests that measuring serum melatonin is a reliable alternative to measuring urinary 6-SMT. However, no differences in clinical benefit between the two dosage groups were demonstrated in the patient reported outcomes. Trial registration number: NCT03498131.
Trends in Dispensing of Zolpidem and Low-Dose Trazodone Among Commercially Insured Adults in the United States, 2011-2018

Jenna Wong,Mara Murray Horwitz,Suzanne M Bertisch,Shoshana J Herzig,Daniel J Buysse,Sengwee Toh

DOI: https://doi.org/10.1001/jama.2020.19224

IF: 11.816

2020-12-01

JAMA

Abstract:This study uses IBM MarketScan database data to describe trends in zolpidem and low-dose trazodone dispensing among adults with employer-sponsored insurance or Medicare supplemental plans between 2011 and 2018, before and after a 2017 clinical practice guideline discouraged trazodone use for insomnia.
Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Yan Li,Zhenbin Xu

DOI: https://doi.org/10.1055/a-1544-8181

2021-09-01

Hormone and Metabolic Research

Abstract:Abstract Insulin resistance (IR) is a pivotal process in various metabolic diseases. The well-known treatment is lifestyle modification and medication therapy, which may result in poor compliance and side effects. Melatonin has been suggested to have a role in glucose metabolism, yet the results across studies have been inconsistent. Therefore, we performed a systematic review to evaluate the effects of melatonin supplementation on insulin levels and IR. We searched PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov, and identified randomized controlled trials (RCTs) published prior to August 2020. Articles were reviewed, selected and extracted by two reviewers independently. In total, 8 RCTs of 376 participants were included. Data were pooled using a random-effects model, with mean differences (MDs) and 95% confidence intervals (CIs). Our results showed that melatonin administration significantly reduced insulin levels and homeostasis model assessment of insulin resistance (HOMA-IR), and increased the quantitative insulin sensitivity check index (QUICKI). We conclude that melatonin ameliorated hyperinsulinemia, insulin resistance, and insulin sensitivity, and the results are an update of a previous meta-analysis. Although more investigations are required, we clearly provide evidence for the use of melatonin as an adjuvant treatment for metabolic disorders involving IR.

endocrinology & metabolism
0805 Melatonin Use Among Children in Foster Care: Associations with Sleep and Daytime Behavior

Carter Baker,Alyssa Vieira,Anthony Cifre,Amy Wolfson,Carol Ripple,Eleanor McGlinchey,Candice Alfano

DOI: https://doi.org/10.1093/sleep/zsae067.0805

IF: 6.313

2024-04-20

SLEEP

Abstract:Abstract Introduction In recent years, melatonin use has risen steeply in children of all ages. It is also the most commonly recommended intervention for sleep problems among children in foster care (Alfano et al., 2022) despite a lack of evidence of its safety and efficacy for children with a history of maltreatment/trauma. This study therefore investigated and compared aspects of sleep and daytime emotional/behavioral problems among children in foster care who have and have not been administered melatonin. Methods Survey data from N=454 caregivers from across the U.S. who were currently fostering children between the ages of 4- and 11-years-old (M=6.39, SD=2.20) were examined (McGlinchey et al., 2023). Caregivers were recruited for an anonymous online survey via private Facebook groups for foster families. Questions included whether or not they had ever administered melatonin to the foster child, aspects of the child’s sleep, and emotional/behavioral problems. Children included in the sample were relatively diverse, with 17% Black/African American and 11% Hispanic children from 46 U.S. states. Results Forty-eight percent (48%; n = 221) of foster caregivers reported administering melatonin to their child currently or in the past. ANCOVAs controlling for level of foster care (i.e., children with special needs) revealed melatonin use was associated with poorer sleep quality, F(1, 423)=25.118, p<.001, partial η2=.056, and increased severity of daytime behavioral problems, F(1, 410)=21.843, p<.001, partial η2=.051, based on medium effects. However, melatonin use was not associated with child depressive, F(1, 441)=2.151, p=.143, partial η2=.005, or anxiety symptoms, F(1, 422)=1.198, p=.274, partial η2=.003. Conclusion Children in foster care who are taking/have taken melatonin are reported to have worse quality sleep and more daytime emotional/behavioral problems than children in foster care not taking melatonin, but not more depressive or anxiety symptoms. The extent to which greater daytime problems might be a result of poorer nighttime sleep remains to be understood. Although our study has limitations, it is one of the first to examine behavioral correlates of melatonin use among children in foster care. Support (if any)

neurosciences,clinical neurology

Trends in Use of Melatonin Supplements Among US Adults, 1999-2018

Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies

0817 Influencing Factors in the Decision-Making Process of U.S. Parents Regarding the Use of Melatonin for Children

Prevalence and trends in dietary supplement use among US adults with diabetes: the National Health and Nutrition Examination Surveys, 1999-2014

A Survey of Melatonin in Dietary Supplement Products Sold in the United States

Melatonin Use in Pediatrics: A Clinical Review on Indications, Multisystem Effects, and Toxicity

Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content.

Melatonin and Age-Related Macular Degeneration Risk

Gender differences in the prevalence of and trends in sleep patterns and prescription medications for insomnia among US adults, 2005 to 2018

Unintended consequences: college students' melatonin usage, sleep disturbance, and depressive symptoms

Patterns of Melatonin Use in a Diverse National Pediatric Sample

Is Melatonin the "Next Vitamin D"?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements

Melatonin Use in School-Aged Children and Adolescents: An Exploration of Caregiver and Pharmacist Perspectives

Quality of melatonin use in children and adolescents: findings from a UK clinical audit

Analysis of sleep for the American population: Result from NHANES database

Notes from the Field: Emergency Department Visits for Unsupervised Pediatric Melatonin Ingestion — United States, 2019–2022

Effect of melatonin supplementation on body composition and blood pressure in adults: A systematic review and Dose-Response meta-analysis of randomized controlled trial

Impact of oral melatonin supplementation on urine and serum melatonin concentrations and quality-of-life measures in persons with relapsing multiple sclerosis

Trends in Dispensing of Zolpidem and Low-Dose Trazodone Among Commercially Insured Adults in the United States, 2011-2018

Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

0805 Melatonin Use Among Children in Foster Care: Associations with Sleep and Daytime Behavior